ASML (ASML) ranks among the highest-rated stocks on the Stoxcraft platform. It carries an overall rating of 8.0 out of 10, a five-star classification that places it in the top tier of the global Technology sector. The stock has also pulled back roughly 10% from its 52-week high after export restriction headlines hit the semiconductor sector. That gap between what the scores say and what the market is doing is the story this week.
What ASML's Health Score of 8.6 tells about the business
Health Score 8.6 doesn't happen by accident. It reflects a business with a structural position unlike almost any other company in global equity markets. To understand why the score sits where it does, you need to understand what ASML actually does.
How ASML's EUV monopoly drives its Health Score in the Technology sector
Extreme ultraviolet lithography is the process used to print chip circuitry at 3 nanometers and below. ASML is the only company in the world that manufactures EUV machines. Not the most advanced one. The only one. Every leading-edge chip from TSMC (TSM), Samsung, SK Hynix, and Intel (INTC) depends entirely on ASML equipment. Replicating an EUV machine requires precision optics developed over decades. A competitor would need at least 10 years to get close. China has been attempting it since 2019.
A Health Score of 8.6 ranks ASML in the top tier of all Technology sector companies in the Stoxcraft universe. The score is driven primarily by exceptional free cash flow generation and gross margins running at around 51%. Those margins rank among the highest in the semiconductor equipment industry. The balance sheet carries minimal leverage. ASML's next-generation machine, High-NA EUV, is already in production and shipping to customers for chips at sub-2nm nodes, extending the moat further.
The €38.8B backlog and what sector-leading cash flow looks like for ASML
ASML's full-year 2026 revenue guidance sits at €34-39 billion. The €38.8B backlog covers the low end of that range in full, with orders extending into 2027. That's more than 12 months of locked-in revenue before a single new booking matters. The Health Score isn't reading export restriction headlines. It's reading the same backlog the bulls are reading.
How ASML's Performance Score of 8.9 compares to the NASDAQ and broader market
A strong business doesn't automatically mean a strong stock. In ASML's case, both have moved in the same direction for years, and the Performance Score captures that consistency.
Consistent outperformance across every major timeframe
Performance Score 8.9 places ASML in the top 10% of the Stoxcraft universe by long-term price momentum. It reflects consistent outperformance against the NASDAQ, S&P 500, and MSCI World over multiple years. That includes the +92% return over the last 12 months. But the outperformance extends much further back. Stocks that rank this high have historically compounded above the market over five-year periods. That kind of consistency is rare across 3,900 stocks.
Why a 6-week pullback doesn't change ASML's five-year performance track record
A minus 6.6% one-month return shows up in the TrendMeter and BuyMeter. Those scores are built to capture short-term signals. The Performance Score reflects what ASML has done against its benchmarks over years. A regulatory headline pullback doesn't close a gap that took five years to build.
ASML's BuyMeter and TrendMeter: what the near-term entry setup looks like
The BuyMeter and TrendMeter are telling a more cautious story than the Health and Performance scores. That split is what makes ASML interesting this week. The near-term signals are responding to a set of real market concerns worth understanding clearly.
The bearish case for ASML: MATCH Act, China revenue, and a 40x forward P/E
US lawmakers introduced the MATCH Act on April 2, 2026. It would block ASML from selling DUV tools to Chinese chipmakers including SMIC, Hua Hong, and YMTC. ASML shares fell as much as 4.7% on that news. Analysts estimate a direct revenue impact of around 5% of total sales if the bill passes in its current form. China was ASML's largest market in 2025 at 33% of total sales, already guided down to ~20% in 2026. Add a forward P/E of around 40x, and the cautious market view has a logical foundation. This is a premium stock that demands premium execution.
What Risk Score 4.9 and BuyMeter 5.9 signal for investors watching ASML
The Risk Score of 4.9 reflects these concerns accurately. Lower is safer on this scale. It sits in the moderate range for the Technology sector, not elevated territory. The main contributors are geopolitical uncertainty, customer concentration, and stretched valuation. The RSI is at 51.8, neutral. The TrendMeter at 5.6 signals a slight uptrend. The BuyMeter at 5.9 registers as a Buy signal, meaning entry looks attractive but not at peak conviction. The +23% YTD run stretched the setup, and the BuyMeter is flagging that tension honestly.
ASML's overall rating of 8.0 and the Quality Compounder thesis
ASML fits the Stoxcraft "Quality Compounder" archetype: high Health Score, high Performance Score, moderate Risk Score. This profile belongs to businesses that compound steadily over years. They don't trade on short-term momentum cycles.
For investors watching ASML, the Quality Compounder label changes the question. It moves the focus from "should I buy this dip?" to "what do I believe about the 3-to-5-year business case?" Health Score 8.6 isn't a trading signal. It's a measure of how strong the underlying engine is. The EUV monopoly, the backlog, and the cash flow are unchanged by a bill that hasn't passed Congress.
Two names worth watching alongside ASML carry very different score profiles, and the contrast is instructive.
Stocks to watch alongside ASML: NVIDIA presents the opposite anomaly
NVIDIA (NVDA) is the clearest contrast. The market is firmly bullish on NVDA. AI chip demand is real and the business is strong. But NVIDIA's Risk Score is elevated relative to Technology sector peers. It reflects high volatility and a demand cycle concentrated in one spending category. The bullish narrative doesn't lead with that. This fits the Stoxcraft Momentum Play archetype: high Performance Score, high TrendMeter, high Risk Score. Comparing ASML and NVDA, the score profiles tell two different stories. One is about structural durability. The other is about momentum in an active cycle. For a deeper look at the semiconductor boom and the companies driving it, see Stoxcraft's chip industry analysis.
What Q1 2026 earnings need to show before the TrendMeter confirms a recovery
TrendMeter 5.6 and BuyMeter 5.9 both sit at the Buy threshold, not a strong-buy signal. Three specific data points from today's Q1 2026 print will determine whether those scores have room to improve:
- Revenue vs. the €8.6B consensus. A beat or in-line result keeps the bullish score thesis intact. A miss gives the bearish narrative more runway.
- Gross margin guidance. High-NA EUV carries higher early production costs. A margin print below the 51-53% guided range would pressure the valuation immediately.
- Full-year commentary. ASML stopped disclosing order bookings this quarter. Management's language on 2026 demand will carry more weight than any single reported number.
If Q1 delivers on all three, the TrendMeter has room to recover. The overall rating of 8.0 doesn't move on one quarter. But the entry setup can, and today's print is the catalyst either way.
Disclaimer: This article is for informational purposes only and does not constitute financial advice or a buy/sell recommendation. Stoxcraft scores are quantitative indicators based on Financial Modeling Prep (FMP) data. All investment decisions should be made based on individual research and risk tolerance.
